Brian P. Sorrentino
Affiliations: | Molecular Therapeutics and Cell Signaling | University of Tennessee Health Science Center, Memphis, TN, United States |
Area:
Molecular Biology, Immunology, Epidemiology, OncologyGoogle:
"Brian Sorrentino"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Bonner MA, Morales-Hernández A, Zhou S, et al. (2021) 3' UTR-truncated HMGA2 overexpression induces non-malignant expansion of hematopoietic stem cells in non-human primates. Molecular Therapy. Methods & Clinical Development. 21: 693-701 |
Ozog S, Timberlake ND, Hermann K, et al. (2019) Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes. Blood |
Mamcarz E, Zhou S, Lockey T, et al. (2019) Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. The New England Journal of Medicine. 380: 1525-1534 |
Fatima S, Zhou S, Sorrentino BP. (2018) Marking of definitive HSC precursors in E7.5-E8.5 embryos using an Abcg2-CreER lineage tracing mouse model. Experimental Hematology |
Fukuda Y, Wang Y, Lian S, et al. (2017) Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis. Jci Insight. 2 |
Mamcarz E, Zhou S, Lockey T, et al. (2017) Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan Blood. 130: 523-523 |
De Ravin SS, Wu X, Moir S, et al. (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Science Translational Medicine. 8: 335ra57 |
Zhou S, Fatima S, Ma Z, et al. (2016) Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes. Molecular Therapy : the Journal of the American Society of Gene Therapy |
Zhou S, Ma Z, Lu T, et al. (2016) 571. Safe Harbor Targeting of IL2RG Expression Cassettes for Gene Therapy of X-Linked Severe Combined Immunodeficiency (SCID-X1) Molecular Therapy. 24: S228 |
Bonner MA, Zhou S, Wang Y, et al. (2016) 281. Enforced Expression of a Mutant HMGA2 Gene Leads to Competitive Expansion and High Level Marking of Long-Term Hematopoietic Stem Cells in Transplanted Nemestrina Macaques Molecular Therapy. 24: S112-S113 |